G Griesinger, C Blockeel, P Pierzynski, H Tournaye, H Višňová, A Humberstone, P Terrill, O Pohl, E Garner, J Donnez, E Loumaye
Human Reproduction, Volume 36, Issue 4, April 2021, Pages 1007–1020
Month: March 2021
PharmaBoardroom interview with Brian O’Callaghan – CEO, ObsEva
Confirmation of the cardiac safety of nolasiban in a randomised cohort of healthy female volunteers
Jörg Täubel, Ulrike Lorch, Christopher S. Spencer, Anne Freier, Dorothée Camilleri, Dilshat Djumanov, Georg Ferber, Line Marchand, Jean-Pierre Gotteland & Oliver Pohl
ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
HCW Presentation March 9, 2021
Year End 2020 Financial Results week of 01 March 2021
Annual Report 2020
ObsEva Announces Year End 2020 Financial Results and Business Update
-Yselty® for uterine fibroids: US New Drug Application filing planned in Q2:21; European marketing approval anticipated in Q4:21- -Yselty® for…
ObsEva to Present at the H.C. Wainwright Global Life Sciences Conference
Geneva, Switzerland and Boston, MA – March 3, 2021 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a biopharmaceutical company…